LeapFinancial | $3,500,000 | (Dec 20, 2024)
TG0 | $5,619,170 | (Dec 20, 2024)
Mindgard | $8,000,000 | (Dec 20, 2024)
Vasa Therapeutics
United States
- California
- 04/01/2024
- Seed
- Undisclosed Amount
Vasa Therapeutics is a San Diego-based, private biotechnology company committed to the discovery and development of therapeutics that target pathophysiology of cardiovascular aging.
Vasa Therapeutics has three active preclinical programs:
1. VS-041 is the first personalized medicine-based treatment of HFpEF. VS-041 shows robust reduction of cardiac fibrosis in a preclinical HFpEF model and inhibits release of signaling collagen fragments, such as PRO-C6, that mediate fibroinflammatory responses and are biomarkers of worse outcomes in HFpEF patients. Phase 1 clinical trial of VS-041 is planned for 2024.
2. Long acting apelin peptide analogs for combination treatment with incretins in obesity patients at risk for skeletal muscle loss or cardiovascular disease. As a monotherapy, long acting apelin agonists could also be beneficial in muscle atrophy, heart failure, chronic kidney disease, and peripheral artery disease.
3. A best-in-class inhibitor of CamKIId for heart failure and life-threatening arrhythmias.
- Industry Biotechnology Research
- Website https://vasatherapeutics.com/
- LinkedIn https://www.linkedin.com/company/vasa-therapeutics/about/
ŌURA | $200,000,000 | (Dec 20, 2024)
Buildpeer | $2,500,000 | (Dec 20, 2024)
Embeddable | $6,238,050 | (Dec 20, 2024)
Tenor | $5,400,000 | (Dec 20, 2024)
SOTELIX Endoscopy | $1,700,000 | (Dec 20, 2024)
Double(US) | $3,900,000 | (Dec 20, 2024)
Hauler Hero | $10,000,000 | (Dec 20, 2024)
TripSuite | $5,000,000 | (Dec 20, 2024)
Seekho | $8,000,000 | (Dec 19, 2024)